"Product prices have continued their downward trend and are now 17.4% cheaper on average than reported in Q3 2019. Patients have also reported significantly increasing their average daily dose, possibly due to price declines making higher doses more affordable."
the post IPO performance of Emerald Clinics (ASX:EMD) shows that the bricks and mortar model is rapidly declining. Cannvalate being the opposite to that and already holding a rough 50% market share will only increase month on month. As others have stated, IHL's relationship cannot be understated!
IHL Price at posting:
5.4¢ Sentiment: Buy Disclosure: Held
